Copy number architectures define treatment-mediated selection of lethal prostate cancer clones

A M Mahedi Hasan1, Paolo Cremaschi1, Daniel Wetterskog1

  • 1University College London Cancer Institute, London, UK.

Nature Communications
|August 10, 2023
PubMed

Insights

Metastatic prostate cancer evolves resistance through diverse genetic changes around the androgen receptor (AR). Copy number alterations reveal distinct clones within patients, suggesting varied lethal trajectories and treatment resistance.

Area of Science:

  • Genomics
  • Cancer Biology
  • Evolutionary Medicine

Background:

  • Metastatic prostate cancer often becomes lethal despite initial hormone therapy.
  • Understanding treatment resistance mechanisms is crucial for improving patient outcomes.

Purpose of the Study:

  • To characterize the genomic evolution of treatment-resistant prostate cancer metastases within individual patients.
  • To identify distinct clones and their evolutionary relationships in lethal prostate cancer.

Main Methods:

  • Genome-wide copy number profiling of 167 metastatic regions from 10 patients.
  • Targeted analysis of androgen receptor (AR) gene alterations.
  • Utilizing genomic boundaries of copy number changes to define clonal clusters.

Main Results:

  • Identified diverse, patient-unique AR alterations in metastases, indicating independent evolution.
  • Confirmed a common origin clone across metastases and diagnostic samples.
  • Discovered clusters of metastases with distinct autosomal copy number alterations and AR gene architectures.
  • Demonstrated topological congruence of autosome-defined clusters, suggesting shared evolutionary paths.

Conclusions:

  • Copy number boundaries can identify treatment-selected clones with distinct lethal trajectories.
  • Genomic divergence patterns correlate with anatomical spread and treatment resistance.
  • Intra-patient heterogeneity in AR alterations drives lethal prostate cancer evolution.